- Home
- MTEX vs BLRX Comparison
MTEX vs BLRX Comparison
Compare MTEX & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEX
- BLRX
- Stock Information
- Founded
- MTEX 1993
- BLRX 2003
- Country
- MTEX United States
- BLRX Israel
- Employees
- MTEX N/A
- BLRX N/A
- Industry
- MTEX Medicinal Chemicals and Botanical Products
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- MTEX Health Care
- BLRX Health Care
- Exchange
- MTEX Nasdaq
- BLRX Nasdaq
- Market Cap
- MTEX 18.2M
- BLRX 17.1M
- IPO Year
- MTEX 1999
- BLRX 2011
- Fundamental
- Price
- MTEX $9.84
- BLRX $3.38
- Analyst Decision
- MTEX
- BLRX Strong Buy
- Analyst Count
- MTEX 0
- BLRX 2
- Target Price
- MTEX N/A
- BLRX $19.00
- AVG Volume (30 Days)
- MTEX 24.2K
- BLRX 24.1K
- Earning Date
- MTEX 11-12-2025
- BLRX 11-24-2025
- Dividend Yield
- MTEX N/A
- BLRX N/A
- EPS Growth
- MTEX N/A
- BLRX N/A
- EPS
- MTEX N/A
- BLRX N/A
- Revenue
- MTEX $110,411,000.00
- BLRX $12,735,000.00
- Revenue This Year
- MTEX N/A
- BLRX N/A
- Revenue Next Year
- MTEX N/A
- BLRX N/A
- P/E Ratio
- MTEX N/A
- BLRX N/A
- Revenue Growth
- MTEX N/A
- BLRX N/A
- 52 Week Low
- MTEX $7.50
- BLRX $2.30
- 52 Week High
- MTEX $16.49
- BLRX $14.70
- Technical
- Relative Strength Index (RSI)
- MTEX 57.80
- BLRX 46.90
- Support Level
- MTEX $9.34
- BLRX $3.20
- Resistance Level
- MTEX $9.86
- BLRX $3.53
- Average True Range (ATR)
- MTEX 0.39
- BLRX 0.21
- MACD
- MTEX 0.03
- BLRX 0.01
- Stochastic Oscillator
- MTEX 95.21
- BLRX 69.77
About MTEX Mannatech Incorporated
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.